Lyell Immunopharma, Inc. (LYEL) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 146770.37%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 146770.37% | Share-based compensation / revenue. Period ending 2026-06-30. $39.63M ÷ $27.00K × 100 ≈ 146770.37% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 27.00K USD | |
| Stock-based compensation | 39.63M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -256.50M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $27.00K | $39.63M | $-256.50M | (m) | (m) | 146770.37% | (m) | (m) |
| 2026-03-31 | (m) | $31.00K | $40.10M | $-256.30M | (m) | (m) | 129354.84% | (m) | (m) |
| 2025-12-31 | (m) | $36.00K | $41.83M | $-269.40M | (m) | (m) | 116191.67% | (m) | (m) |
| 2025-09-30 | (m) | $41.00K | $24.34M | $-342.91M | (m) | (m) | 59373.17% | (m) | (m) |
| 2025-06-30 | (m) | $60.00K | $26.73M | $-356.16M | (m) | (m) | 44555.00% | (m) | (m) |
| 2025-03-31 | (m) | $65.00K | $30.01M | $-360.55M | (m) | (m) | 46173.85% | (m) | (m) |
| 2024-12-31 | (m) | $61.00K | $33.14M | $-358.75M | (m) | (m) | 54334.43% | (m) | (m) |
| 2024-09-30 | $169.93M | $63.00K | $33.52M | $-217.12M | (m) | 269730.16% | 53212.70% | (m) | (m) |
| 2024-06-30 | $174.28M | $54.00K | $36.42M | $-225.65M | (m) | 322738.89% | 67440.74% | (m) | (m) |
| 2024-03-31 | $181.49M | $68.00K | $42.36M | $-240.03M | (m) | 266895.59% | 62289.71% | (m) | (m) |
| 2023-12-31 | $182.94M | $130.00K | $47.08M | $-247.01M | (m) | 140726.92% | 36218.46% | (m) | (m) |
| 2023-09-30 | $173.98M | $48.50M | $56.98M | $-202.28M | (m) | 358.70% | 117.49% | (m) | (m) |
| 2023-06-30 | $171.74M | $48.48M | $65.59M | $-209.68M | (m) | 354.24% | 135.29% | (m) | (m) |
| 2023-03-31 | $167.99M | $84.19M | $73.78M | $-181.04M | (m) | 199.52% | 87.63% | (m) | (m) |
| 2022-12-31 | $159.19M | $84.68M | $81.92M | $-187.06M | (m) | 187.98% | 96.74% | (m) | (m) |
| 2022-09-30 | $140.44M | $39.12M | $84.74M | $-219.81M | (m) | 359.01% | 216.62% | (m) | (m) |
| 2022-06-30 | $130.27M | $41.87M | $78.66M | $-202.54M | (m) | 311.12% | 187.86% | (m) | (m) |
| 2022-03-31 | $132.99M | $8.76M | $71.50M | $-227.98M | (m) | 1518.54% | 816.36% | (m) | (m) |
| 2021-12-31 | $138.69M | $10.65M | $62.20M | $-214.78M | (m) | 1302.28% | 584.05% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $182.24M | $7.76M | $33.26M | $-211.94M | (m) | 2349.70% | 428.84% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $63.59M | $657.00K | $15.73M | $-102.09M | (m) | 9679.60% | 2394.52% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |